BACKGROUND: Acute myeloid leukemia (AML) remains a major therapeutic challenge in pediatric oncology even with intensified cytarabine (ara-C)-based chemotherapy. Therefore, new therapies are urgently needed to improve treatment outcome of this deadly disease. In this study, we evaluated antileukemic interactions between clofarabine (a second-generation purine nucleoside analog) and valproic acid (VPA, a FDA-approved agent for treating epilepsy in both children and adult and a histone deacetylase inhibitor), in pediatric AML. METHODOLOGY: In vitro clofarabine and VPA cytotoxicities of the pediatric AML cell lines and diagnostic blasts were measured by using MTT assays. The effects of clofarabine and VPA on apoptosis and DNA double strand breaks (DSBs) were determined by flow cytometry analysis and Western blotting, respectively. Active form of Bax was measured by Western blotting post-immunoprecipitation. RESULTS: We demonstrated synergistic antileukemic activities between clofarabine and VPA in both pediatric AML cell lines and diagnostic blasts sensitive to VPA. In contrast, antagonism between the two agents could be detected in AML cells resistant to VPA. Clofarabine and VPA cooperate in inducing DNA DSBs, accompanied by Bax activation and apoptosis in pediatric AML cells. CONCLUSION: Our results document synergistic antileukemic activities of combined VPA and clofarabine in pediatric AML and suggest that this combination could be an alternative treatment option for the disease.
BACKGROUND:Acute myeloid leukemia (AML) remains a major therapeutic challenge in pediatric oncology even with intensified cytarabine (ara-C)-based chemotherapy. Therefore, new therapies are urgently needed to improve treatment outcome of this deadly disease. In this study, we evaluated antileukemic interactions between clofarabine (a second-generation purine nucleoside analog) and valproic acid (VPA, a FDA-approved agent for treating epilepsy in both children and adult and a histone deacetylase inhibitor), in pediatric AML. METHODOLOGY: In vitro clofarabine and VPAcytotoxicities of the pediatric AML cell lines and diagnostic blasts were measured by using MTT assays. The effects of clofarabine and VPA on apoptosis and DNA double strand breaks (DSBs) were determined by flow cytometry analysis and Western blotting, respectively. Active form of Bax was measured by Western blotting post-immunoprecipitation. RESULTS: We demonstrated synergistic antileukemic activities between clofarabine and VPA in both pediatric AML cell lines and diagnostic blasts sensitive to VPA. In contrast, antagonism between the two agents could be detected in AML cells resistant to VPA. Clofarabine and VPA cooperate in inducing DNA DSBs, accompanied by Bax activation and apoptosis in pediatric AML cells. CONCLUSION: Our results document synergistic antileukemic activities of combined VPA and clofarabine in pediatric AML and suggest that this combination could be an alternative treatment option for the disease.
Authors: Peter L Bonate; Larry Arthaud; William R Cantrell; Katherine Stephenson; John A Secrist; Steve Weitman Journal: Nat Rev Drug Discov Date: 2006-10 Impact factor: 84.694
Authors: Leigh Ellis; Yan Pan; Gordon K Smyth; Daniel J George; Chris McCormack; Roxanne Williams-Truax; Monica Mita; Joachim Beck; Howard Burris; Gail Ryan; Peter Atadja; Dale Butterfoss; Margaret Dugan; Kenneth Culver; Ricky W Johnstone; H Miles Prince Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: Holly Edwards; Chengzhi Xie; Katherine M LaFiura; Alan A Dombkowski; Steven A Buck; Julie L Boerner; Jeffrey W Taub; Larry H Matherly; Yubin Ge Journal: Blood Date: 2009-07-28 Impact factor: 22.113
Authors: Judith E Karp; Rebecca M Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer; Steven D Gore; B Douglas Smith; Michael A McDevitt; Hetty Carraway; Mark J Levis; Varsha Gandhi Journal: Blood Date: 2007-06-11 Impact factor: 22.113
Authors: Alfonso Duenas-Gonzalez; Myrna Candelaria; Carlos Perez-Plascencia; Enrique Perez-Cardenas; Erick de la Cruz-Hernandez; Luis A Herrera Journal: Cancer Treat Rev Date: 2008-01-15 Impact factor: 12.111
Authors: Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt Journal: Pharmaceuticals (Basel) Date: 2021-05-02
Authors: Chengzhi Xie; Christina Drenberg; Holly Edwards; J Timothy Caldwell; Wei Chen; Hiroto Inaba; Xuelian Xu; Steven A Buck; Jeffrey W Taub; Sharyn D Baker; Yubin Ge Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: Marije Bartels; Anita Govers; Roel Polak; Stephin Vervoort; Ruben van Boxtel; Cornelieke Pals; Marc Bierings; Wouter van Solinge; Toine Egberts; Edward Nieuwenhuis; Michal Mokry; Paul James Coffer Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240